

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
15 February 2001 (15.02.2001)

PCT

(10) International Publication Number
WO 01/11085 A2

(51) International Patent Classification⁷: **C12Q 1/68**,
A61K 38/18, A61P 25/18, A61K 48/00, G01N 33/53

(74) Agents: **HOGLE, Doreen, M. et al.**; Hamilton, Brook,
Smith & Reynolds, P.C., Two Militia Drive, Lexington, MA
02421 (US).

(21) International Application Number: **PCT/US00/21859**

(22) International Filing Date: **11 August 2000 (11.08.2000)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
60/148,389 **11 August 1999 (11.08.1999)** **US**

(71) Applicant (for all designated States except US): **WHITE-
HEAD INSTITUTE FOR BIOMEDICAL RESEARCH**
[US/US]; Nine Cambridge Center, Cambridge, MA 02142
(US).

(81) Designated States (national): **AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.**

(84) Designated States (regional): **ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).**

Published:

*Without international search report and to be republished
upon receipt of that report.*

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(72) Inventors; and

(75) Inventors/Applicants (for US only): **SKLAR, Pamela**
[US/US]; 68 Fuller Street, Brookline, MA 02446 (US).
LANDER, Eric, S. [US/US]; 151 Bishop Allen Drive,
Cambridge, MA 02139 (US).

WO 01/11085 A2

(54) Title: **BDNF POLYMORPHISM AND ASSOCIATION WITH BIPOLAR DISORDER**

(57) Abstract: Methods for diagnosing and treating neuropsychiatric disorders, especially bipolar disorder, and to methods for identifying compounds for use in the diagnosis and treatment of neuropsychiatric disorders are disclosed. Also disclosed are novel compounds and pharmaceutical compositions for use in the diagnosis and treatment of neuropsychiatric disorders such as bipolar disorder.

AN

BDNF POLYMORPHISM AND ASSOCIATION WITH BIPOLAR DISORDER RELATED APPLICATION

This application claims benefit of U.S. Provisional application 60/148,389,
filed August 11, 1999, the entire teachings of which are incorporated herein by
5 reference.

BACKGROUND OF THE INVENTION

Modern psychiatry typically subdivides mood disorders into bipolar disorders
(episodes of mania or both mania and depression) and unipolar depressive disorder
(episodes of depression). Symptoms of mania include expansive, elevated or
10 irritable mood, inflated self-esteem, grandiosity, decreased need for sleep, increased
talkativeness, racing thoughts, distractibility, increased goal-directed activity, and
excessive involvement in pleasurable activities with a high potential for painful
consequences. Depressive symptoms include depressed mood, diminished interest
or pleasure in activities, insomnia or hypersomnia, psychomotor agitation or
15 retardation, fatigue or loss of energy, feelings of worthlessness, excessive guilt,
inability to concentrate or act decisively, and recurrent thoughts of death or suicide.
Several mental disorders have been proposed as alternate expressions of a bipolar
genotype, including variants of schizoaffective disorder, recurrent unipolar
depression and hypomania (bipolar II disorder).

20 Neuropsychiatric disorders, such as schizophrenia, attention deficit disorders,
schizoaffective disorders, bipolar disorders and unipolar disorders, differ from
neurological disorders in that anatomical or biochemical pathologies are readily

detectable for the latter but not the former. Largely as a result of this difference, drugs which have been used to treat individuals with neuropsychiatric disorders, including lithium salts, valproic acid and carbamazepine, have not been predictably effective in treatment regimens across a variety of patients. Treatment regimens are further complicated by the fact that clinical diagnosis currently relies on clinical observation and subjective reports. Identification of the anatomical or biochemical defects which result in neuropsychiatric disorders is needed in order to effectively distinguish between the disorders and to allow the design and administration of effective therapeutics for these disorders.

10 SUMMARY OF THE INVENTION

As described herein, it has been discovered that a polymorphism in the gene for brain-derived neurotrophic factor (BDNF) is negatively correlated with incidence of neuropsychiatric disorders (e.g., bipolar disorder). In particular, it has been discovered that one or more single nucleotide polymorphisms within the nucleotide sequence encoding the 132 amino acid prepro portion of the BDNF gene product is correlated with reduced incidence of bipolar disorder in a sample population assessed as described herein. In one embodiment, a single nucleotide polymorphism from G to A at nucleotide position 424, resulting in an amino acid change from valine to methionine at amino acid position -63 (relative to the start of the mature protein), is correlated with a reduced incidence of bipolar disorder in the sample population assessed as described herein. That is, it has been determined that there is a variation from random (i.e., that which would be expected by chance) in the transmission of the reference (G) and variant (A) alleles from a parent who is heterozygous for the BDNF alleles to an offspring diagnosed with bipolar disorder. The variant allele (A) is transmitted less frequently (34 of 98 times) to the bipolar offspring than would be expected by chance, while the reference allele (G) is transmitted more frequently (64 of 98 times) than would be expected by chance ($p=0.004$). Thus, it appears that the variant allele may contribute to protection or reduction in symptomology with respect to bipolar disorder. Alternatively, this particular polymorphism may be one of a group of two or more polymorphisms in

the BDNF gene which contributes to the presence, absence or severity of the neuropsychiatric disorder, e.g., bipolar disorder.

Accordingly, the invention relates to methods for diagnosing and treating neuropsychiatric disorders, especially bipolar disorder, and to methods for
5 identifying compounds for use in the diagnosis and treatment of neuropsychiatric disorders. The invention relates to novel compounds and pharmaceutical compositions for use in the diagnosis and treatment of neuropsychiatric disorders. The invention further relates to kits for use in diagnosing neuropsychiatric disorders. In a preferred embodiment, the neuropsychiatric disorder is bipolar disorder.

10 In one embodiment, the invention relates to a method for predicting the likelihood that an individual will have a neuropsychiatric disorder (or aiding in the diagnosis of a neuropsychiatric disorder), e.g., bipolar disorder, comprising the steps of obtaining a DNA sample from an individual to be assessed and determining the nucleotide present at nucleotide position 424 of the BDNF gene. The presence of an
15 "A" (the variant nucleotide) at position 424 indicates that the individual has a lower likelihood of having a neuropsychiatric disorder than an individual having a "G" at that position, or a greater likelihood of having less severe symptomology. In a preferred embodiment, the neuropsychiatric disorder is bipolar disorder. In a particular embodiment, the individual is an individual at risk for development of
20 bipolar disorder.

In another embodiment, the invention relates to pharmaceutical compositions comprising a variant BDNF gene product for use in the treatment of neuropsychiatric disorders. In one embodiment, the gene product is a peptide comprising amino acids -1 through -132, or a functional portion thereof, of a variant BDNF gene product for
25 use in the treatment of neuropsychiatric disorders. The invention further relates to the use of compositions (i.e., agonists and antagonists) which enhance or increase or which reduce or decrease, respectively, the activity of a peptide comprising amino acids -1 through -132, or a functional portion thereof, of a variant BDNF gene product for use in the treatment of neuropsychiatric disorders. The invention also
30 relates to the use of a nucleic acid molecule encoding a variant BDNF gene product for use in the treatment of neuropsychiatric disorders. In one embodiment, the gene

product is a peptide comprising amino acids -1 through -132, or a functional portion thereof, of a variant BDNF gene product. In a particular embodiment the neuropsychiatric disorder is bipolar disorder.

In another embodiment, the invention relates to a method for predicting the
5 likelihood that an individual will have a neuropsychiatric disorder by determining the presence of prepro BDNF or fragment thereof containing the reference or variant amino acid at position -63. The method comprises obtaining a sample from an individual to be assessed, wherein the sample comprises prepro BDNF protein or fragment thereof, wherein said fragment includes amino acid -63 of prepro BDNF
10 protein. The amino acid present at amino acid -63 of said prepro BDNF is determined, wherein the presence of an methionine at position -63 indicates that the individual has a lower likelihood of developing a neuropsychiatric disorder than an individual having a valine at that position. In one embodiment, the amino acid present at amino acid -63 is determined by contacting the sample with an antibody
15 specific for prepro BDNF or fragment thereof containing the reference amino acid. In another embodiment, the amino acid present at amino acid -63 is determined by contacting the sample with an antibody specific for prepro BDNF or fragment thereof containing the variant amino acid.

In another embodiment, the invention is drawn to a method of predicting the
20 likelihood that an individual will have reduced symptomology associated with a neuropsychiatric disorder, comprising determining the presence of prepro BDNF or fragment thereof containing the reference or variant amino acid as described above. The presence of an methionine at position -63 indicates that the individual has a greater likelihood of having reduced symptomology associated with a
25 neuropsychiatric disorder than an individual having a valine at that position.

The invention is also drawn to kits for use the methods of the present invention. In one embodiment, the kit comprises a nucleic acid probe, wherein said probe allows the identification of the nucleotide at position 424 of the BDNF gene. The kit can also include control nucleic acid samples. The control nucleic acid
30 samples can include, for example, the homozygous reference genotype, homozygous

variant genotype and the heterozygous genotype at nucleotide position 424 of the BDNF gene. In one embodiment the kit comprises control nucleic acid samples representing the genotype of at least one of the group consisting of: an individual homozygous for a "A" at nucleotide position 424 of a BDNF gene, an individual
5 homozygous for a "G" at nucleotide position 424 of a BDNF gene and an individual heterozygous for said position. In one embodiment, the kit comprises a probe that is an SBE-FRET primer. In more specific embodiment, the probe comprises SEQ ID NO: 11.

In another embodiment, the kit comprises at least one antibody, selected
10 from the group consisting of: an antibody specific for a prepro portion of BDNF or fragment thereof, wherein said prepro portion of BDNF or fragment thereof comprises a methionine at amino acid position -63 and an antibody specific for a prepro portion or fragment thereof of BDNF, wherein said prepro portion or fragment there comprises a valine at amino acid position -63. The kit can also
15 comprise control protein samples representing the genotype of at least one of the group consisting of: an individual homozygous for a nucleic acid sequence encoding a methionine at amino acid position -63 of prepro BDNF protein, an individual homozygous for a nucleic acid sequence encoding a valine at amino acid position -63 of prepro BDNF protein and an individual heterozygous for said
20 position.

BRIEF DESCRIPTION OF THE DRAWINGS

Figures 1A and 1B are an illustration (from Maisonpierre *et al.*, *Genomics* 10:558-568 (1991)) of the nucleotide and amino acid sequences of the human and rat BDNF genomic and cDNA clones compared to the pig and mouse cDNA sequences,
25 wherein the sequences are read as shown by the arrows.

Figure 2A shows data resulting from a genotyping assessment of the reference and variant alleles of BDNF in a group of trios having one or more bipolar offspring as described in the Examples.

Figure 2B shows data resulting from a genotyping assessment of the reference and variant alleles of BDNF in a group of trios having one or more bipolar offspring as described in the Examples.

Figure 3 shows the data resulting from a genotyping assessment of the reference and variant alleles of BDNF in an additional group of trios having one or more bipolar offspring as described in the Examples.

Figure 4 shows the estimated relative risk of developing bipolar disorder based on data and analyses from the indicated groups of affected individuals and described in the Exemplification.

10 DETAILED DESCRIPTION OF THE INVENTION

The development and maintenance of the vertebrate nervous system depends, in part, on the physiological availability of neuronal survival proteins known as neurotrophic factors. Neurotrophic factors play a role in maintaining neurons and their differentiated phenotypes in the adult nervous system. Nerve growth factor (NGF) remains the best characterized neurotrophic factor. However, brain-derived neurotrophic factor (BDNF) has been cloned and shown to be homologous to NGF (Leibrock *et al.*, *Nature* 341:149-152 (1989); Hofer *et al.*, *EMBO J.* 9:2459-2464 (1990); Maisonpierre *et al.*, *Genomics* 10:558-568 (1991)). BDNF is initially synthesized as a 251 amino acid protein precursor that is subsequently cleaved to yield the mature protein. The mature form of BDNF essentially corresponds to the C-terminal half of its precursor and comprises 119 amino acids. In the developing rat, BDNF expression undergoes an increase from initially low levels, and in the adult rat central nervous system, BDNF is expressed at its highest level in the hippocampus. Expression of BDNF is detectable in adult tissues outside of the central nervous system only in heart, lung and skeletal muscle (Maisonpierre *et al.*, *Science* 247:1446-1451 (1990); Hofer *et al.*, *EMBO J.* 9:2459-2464 (1990)).

As shown in Figures 1A and 1B, the human genomic sequence of BDNF is SEQ ID NO: 1, the human cDNA sequence is SEQ ID NO: 2, the rat genomic sequence is SEQ ID NO: 3, the rat cDNA sequence is SEQ ID NO: 4, the mouse cDNA sequence is SEQ ID NO: 5, and the pig cDNA sequence is SEQ ID NO: 6.

The human amino acid sequence is SEQ ID NO: 7, the rat amino acid sequence is SEQ ID NO: 8, the mouse amino acid sequence is SEQ ID NO: 9, and the pig amino acid sequence is SEQ ID NO: 10. Sequences are designated with a lowercase letter signifying species, an uppercase "B" for BDNF, and a G or a C in parentheses distinguishing between either a genomic or cDNA source for the sequence. DNA sequence identities to the top human sequence are indicated by a dot, and gaps are indicated by a dash. In-frame stop codons in the upstream regions are underlined. Amino acid translation is indicated above the human nucleotide sequence; only amino acid differences with the human sequence are indicated for the other sequences. Amino acids are numbered with position +1 assigned to the first residue in the mature protein sequence. RNA splice sites (SPLICE1 and SPLICE2), the B start site, the consensus protein glycosylation signal, and the consensus protein cleavage signal involved in release of the mature BDNF are indicated. Only sequence flanking splice site 1 is shown for the human and rat genomic clones, since this is the only region in which they differ from their respective cDNA sequences. An exception to this is the presence of a single mismatch (A for G) between the human BDNF genomic and cDNA sequence at nucleotide position 424, resulting in the substitution of a methionine residue for a valine residue at amino acid position -63 in the genomic-derived protein sequence.

As used herein, polymorphism refers to the occurrence of two or more genetically determined alternative sequences or alleles in a population. A polymorphic marker or site is the locus at which divergence occurs. Preferred markers have at least two alleles, each occurring at frequency of greater than 1%, and more preferably greater than 10% or 20% of a selected population. A polymorphic locus may be as small as one base pair, in which case it is referred to as a single nucleotide polymorphism.

As described herein, it has been discovered that a polymorphism in the gene for BDNF is negatively correlated with incidence of neuropsychiatric disorders (e.g., bipolar disorder). In particular, it has been discovered that one or more single nucleotide polymorphisms within the nucleotide sequence encoding the 132 amino acid prepro portion of the BDNF gene product are correlated with a reduced

incidence of bipolar disorder in the sample population assessed as described herein. In one embodiment, a single polymorphism from G to A at nucleotide position 424 in Figure 1, or at a nucleotide position corresponding thereto, resulting in an amino acid change from valine to methionine at amino acid position -63 (relative to the start of the mature protein; see Figure 1), or at an amino acid position corresponding thereto, is correlated with a reduced incidence of bipolar disorder in the sample population assessed as described herein. This polymorphism resides within the 132 amino acid precursor portion (the prepro portion) which is cleaved from the mature protein.

Data from the work described herein has shown that there is a variation from random (i.e., that which would be expected by chance) in the transmission of the reference (G) and variant (A) alleles from a parent who is heterozygous for the BDNF alleles to an offspring diagnosed with bipolar disorder. The variant allele (A) is transmitted less frequently (34 of 98 times) to the bipolar offspring than would be expected by chance, while the reference allele (G) is transmitted more frequently (64 of 98 times) than would be expected by chance ($p=0.004$). Thus, it appears that the variant allele may contribute to protection or reduction in symptomology with respect to bipolar disorder. Alternatively, this particular polymorphism may be one of a group of two or more polymorphisms in the BDNF gene which contributes to the presence, absence or severity of the neuropsychiatric disorder, e.g., bipolar disorder.

Thus, the invention relates to a method for predicting the likelihood that an individual will have a neuropsychiatric disorder, or for aiding in the diagnosis of a neuropsychiatric disorder, e.g., bipolar disorder, or a greater likelihood of having reduced symptomology associated with a neuropsychiatric disorder, e.g., bipolar disorder, comprising the steps of obtaining a DNA sample from an individual to be assessed and determining the nucleotide present at nucleotide position 424 of the brain-derived neurotrophic factor (BDNF) gene. The presence of an "A" (the variant nucleotide) at position 424 indicates that the individual has a lower likelihood of having a neuropsychiatric disorder, or a greater likelihood of having reduced symptomology associated with a neuropsychiatric disorder, than if that individual

had the reference nucleotide at that position. Conversely, the presence of a "G" (the reference nucleotide) at position 424 indicates that the individual has a greater likelihood of having a neuropsychiatric disorder, or a likelihood of having increased symptomology associated with a neuropsychiatric disorder, than if that individual
5 had the variant nucleotide at that position. In a preferred embodiment, the neuropsychiatric disorder is bipolar disorder. In a particular embodiment, the individual is an individual at risk for development of bipolar disorder. In another embodiment the individual exhibits clinical symptomology associated with bipolar disorder. In one embodiment, the individual has been clinically diagnosed as having
10 bipolar disorder.

The genetic material to be assessed can be obtained from any nucleated cell from the individual. For assay of genomic DNA, virtually any biological sample (other than pure red blood cells) is suitable. For example, convenient tissue samples include whole blood, semen, saliva, tears, urine, fecal material, sweat, skin and hair.
15 For assay of cDNA or mRNA, the tissue sample must be obtained from an organ in which the target nucleic acid is expressed. For example, cells from the central nervous system (such as cells of the hippocampus), neural crest-derived cells, skin, heart, lung and skeletal muscle are suitable sources for obtaining cDNA for the BDNF gene. Neural crest derived cells include, for example, melanocytes and
20 keratinocytes.

Many of the methods described herein require amplification of DNA from target samples. This can be accomplished by e.g., PCR. *See generally PCR Technology: Principles and Applications for DNA Amplification* (ed. H.A. Erlich, Freeman Press, NY, NY, 1992); *PCR Protocols: A Guide to Methods and*
25 *Applications* (eds. Innis, *et al.*, Academic Press, San Diego, CA, 1990); Mattila *et al.*, *Nucleic Acids Res.* 19, 4967 (1991); Eckert *et al.*, *PCR Methods and Applications* 1, 17 (1991); *PCR* (eds. McPherson *et al.*, IRL Press, Oxford); and U.S. Patent 4,683,202.

Other suitable amplification methods include the ligase chain reaction (LCR)
30 (see Wu and Wallace, *Genomics* 4, 560 (1989), Landegren *et al.*, *Science* 241, 1077 (1988), transcription amplification (Kwoh *et al.*, *Proc. Natl. Acad. Sci. USA* 86,

1173 (1989)), and self-sustained sequence replication (Guatelli *et al.*, *Proc. Nat. Acad. Sci. USA*, 87, 1874 (1990)) and nucleic acid based sequence amplification (NASBA). The latter two amplification methods involve isothermal reactions based on isothermal transcription, which produce both single stranded RNA (ssRNA) and
5 double stranded DNA (dsDNA) as the amplification products in a ratio of about 30 or 100 to 1, respectively.

The nucleotide which occupies the polymorphic site of interest (e.g., nucleotide position 424 in BDNF) can be identified by a variety methods, such as Southern analysis of genomic DNA; direct mutation analysis by restriction enzyme
10 digestion; Northern analysis of RNA; denaturing high pressure liquid chromatography (DHPLC); gene isolation and sequencing; hybridization of an allele-specific oligonucleotide with amplified gene products; single base extension (SBE); or analysis of the BDNF protein. In a preferred embodiment, determination of the allelic form of BDNF is carried out using SBE-FRET methods as described in
15 the examples, or using chip-based oligonucleotide arrays. A sampling of suitable procedures are discussed below in turn.

1. Allele-Specific Probes

The design and use of allele-specific probes for analyzing polymorphisms is described by e.g., Saiki *et al.*, *Nature* 324, 163-166 (1986); Dattagupta, EP 235,726,
20 Saiki, WO 89/11548. Allele-specific probes can be designed that hybridize to a segment of target DNA from one individual but do not hybridize to the corresponding segment from another individual due to the presence of different polymorphic forms in the respective segments from the two individuals. Hybridization conditions should be sufficiently stringent that there is a significant
25 difference in hybridization intensity between alleles, and preferably an essentially binary response, whereby a probe hybridizes to only one of the alleles. Hybridizations are usually performed under stringent conditions, for example, at a salt concentration of no more than 1 M and a temperature of at least 25°C. For example, conditions of 5X SSPE (750 mM NaCl, 50 mM NaPhosphate, 5 mM
30 EDTA, pH 7.4) and a temperature of 25-30°C, or equivalent conditions, are suitable

for allele-specific probe hybridizations. Equivalent conditions can be determined by varying one or more of the parameters given as an example, as known in the art, while maintaining a similar degree of identity or similarity between the target nucleotide sequence and the primer or probe used.

- 5 Some probes are designed to hybridize to a segment of target DNA such that the polymorphic site aligns with a central position (e.g., in a 15-mer at the 7 position; in a 16-mer, at either the 8 or 9 position) of the probe. This design of probe achieves good discrimination in hybridization between different allelic forms.

- Allele-specific probes are often used in pairs, one member of a pair showing
10 a perfect match to a reference form of a target sequence and the other member showing a perfect match to a variant form. Several pairs of probes can then be immobilized on the same support for simultaneous analysis of multiple polymorphisms within the same target sequence.

2. Tiling Arrays

- 15 The polymorphisms can also be identified by hybridization to nucleic acid arrays, some examples of which are described in WO 95/11995. WO 95/11995 also describes subarrays that are optimized for detection of a variant form of a precharacterized polymorphism. Such a subarray contains probes designed to be complementary to a second reference sequence, which is an allelic variant of the first
20 reference sequence. The second group of probes is designed by the same principles, except that the probes exhibit complementarity to the second reference sequence. The inclusion of a second group (or further groups) can be particularly useful for analyzing short subsequences of the primary reference sequence in which multiple mutations are expected to occur within a short distance commensurate with the
25 length of the probes (e.g., two or more mutations within 9 to 21 bases).

3. Allele-Specific Primers

An allele-specific primer hybridizes to a site on target DNA overlapping a polymorphism and only primes amplification of an allelic form to which the primer exhibits perfect complementarity. See Gibbs, *Nucleic Acid Res.* 17, 2427-2448

(1989). This primer is used in conjunction with a second primer which hybridizes at a distal site. Amplification proceeds from the two primers, resulting in a detectable product which indicates the particular allelic form is present. A control is usually performed with a second pair of primers, one of which shows a single base mismatch at the polymorphic site and the other of which exhibits perfect complementarity to a distal site. The single-base mismatch prevents amplification and no detectable product is formed. The method works best when the mismatch is included in the 3'-most position of the oligonucleotide aligned with the polymorphism because this position is most destabilizing to elongation from the primer (see, e.g., WO 93/22456).

4. Direct-Sequencing

The direct analysis of the sequence of polymorphisms of the present invention can be accomplished using either the dideoxy chain termination method or the Maxam Gilbert method (see Sambrook *et al.*, *Molecular Cloning, A Laboratory Manual* (2nd Ed., CSHP, New York 1989); Zyskind *et al.*, *Recombinant DNA Laboratory Manual*, (Acad. Press, 1988)).

5. Denaturing Gradient Gel Electrophoresis

Amplification products generated using the polymerase chain reaction can be analyzed by the use of denaturing gradient gel electrophoresis. Different alleles can be identified based on the different sequence-dependent melting properties and electrophoretic migration of DNA in solution. Erlich, ed., *PCR Technology, Principles and Applications for DNA Amplification*, (W.H. Freeman and Co, New York, 1992), Chapter 7.

6. Single-Strand Conformation Polymorphism Analysis

Alleles of target sequences can be differentiated using single-strand conformation polymorphism analysis, which identifies base differences by alteration in electrophoretic migration of single stranded PCR products, as described in Orita *et al.*, *Proc. Nat. Acad. Sci.* 86, 2766-2770 (1989). Amplified PCR products can be

generated as described above, and heated or otherwise denatured, to form single stranded amplification products. Single-stranded nucleic acids may refold or form secondary structures which are partially dependent on the base sequence. The different electrophoretic mobilities of single-stranded amplification products can be related to base-sequence differences between alleles of target sequences.

The polymorphism of the invention may contribute to the protection of an individual against bipolar disorder in different ways. The polymorphism may contribute to phenotype by affecting protein structure. By altering amino acid sequence, the polymorphism may alter the function of the encoded protein. The polymorphism may exert phenotypic effects indirectly via influence on replication, transcription, and translation. For example, the substitution of a methionine for a valine in the prepro portion of the BDNF gene product may create an alternative translation start site which alters the length of the gene product and the prepro portion itself. Alteration of the length of the gene product may affect cleavage of the mature protein either positively or negatively. Alternatively, the presence of the variant amino acid may alter the properties of the gene product so as to alter cleavage of the gene product. More than one phenotypic trait may be affected. For example, other neuropsychiatric disorders which are believed to be alternate expressions of a bipolar genotype, including variants of schizoaffective disorder, recurrent unipolar depression and hypomania (bipolar II disorder), may also be affected by the BDNF polymorphism described herein. Additionally, the described polymorphism may predispose an individual to a distinct mutation that is causally related to a certain phenotype, such as susceptibility or resistance to bipolar disorder. The discovery of the polymorphism and its correlation with bipolar disorder facilitates biochemical analysis of the variant and the development of assays to characterize the variant and to screen for pharmaceuticals that interact directly with one or another form of the protein.

Alternatively, this particular polymorphism may be one of a group of two or more polymorphisms in the BDNF gene which contributes to the presence, absence or severity of the neuropsychiatric disorder, e.g., bipolar disorder. An assessment of other polymorphisms within the BDNF gene can be undertaken, and the separate and

combined effects of these polymorphisms on the neuropsychiatric disorder phenotype can be assessed.

Correlation between a particular phenotype, e.g., the bipolar phenotype, and the presence or absence of a particular allele is performed for a population of
5 individuals who have been tested for the presence or absence of the phenotype. Correlation can be performed by standard statistical methods such as a Chi-squared test and statistically significant correlations between polymorphic form(s) and phenotypic characteristics are noted. For example, as described herein, it has been found that the presence of the BDNF variant allele, having an A at polymorphic site
10 424, correlates negatively with bipolar disorder with a p value of $p=0.004$ by Chi-squared test.

This correlation can be exploited in several ways. In the case of a strong correlation between a particular polymorphic form, e.g., the reference allele for BDNF, and a disease for which treatment is available, e.g., bipolar disorder,
15 detection of the polymorphic form in an individual may justify immediate administration of treatment, or at least the institution of regular monitoring of the individual. Detection of a polymorphic form correlated with a disorder in a couple contemplating a family may also be valuable to the couple in their reproductive decisions. For example, the female partner might elect to undergo *in vitro*
20 fertilization to avoid the possibility of transmitting such a polymorphism from her husband to her offspring. In the case of a weaker, but still statistically significant correlation between a polymorphic form and a particular disorder, immediate therapeutic intervention or monitoring may not be justified. Nevertheless, the individual can be motivated to begin simple life-style changes (e.g., therapy or
25 counseling) that can be accomplished at little cost to the individual but confer potential benefits in reducing the risk of conditions to which the individual may have increased susceptibility by virtue of the particular allele. Furthermore, identification of a polymorphic form correlated with enhanced receptiveness to one of several treatment regimes for a disorder indicates that this treatment regime should be
30 followed for the individual in question.

Furthermore, it may be possible to identify a physical linkage between a genetic locus associated with a trait of interest (e.g., bipolar disorder) and polymorphic markers that are not associated with the trait, but are in physical proximity with the genetic locus responsible for the trait and co-segregate with it.

- 5 Such analysis is useful for mapping a genetic locus associated with a phenotypic trait to a chromosomal position, and thereby cloning gene(s) responsible for the trait. See Lander *et al.*, *Proc. Natl. Acad. Sci. (USA)* 83, 7353-7357 (1986); Lander *et al.*, *Proc. Natl. Acad. Sci. (USA)* 84, 2363-2367 (1987); Donis-Keller *et al.*, *Cell* 51, 319-337 (1987); Lander *et al.*, *Genetics* 121, 185-199 (1989)). Genes localized by
10 linkage can be cloned by a process known as directional cloning. See Wainwright, *Med. J. Australia* 159, 170-174 (1993); Collins, *Nature Genetics* 1, 3-6 (1992).

- Linkage studies are typically performed on members of a family. Available members of the family are characterized for the presence or absence of a phenotypic trait and for a set of polymorphic markers. The distribution of polymorphic markers
15 in an informative meiosis is then analyzed to determine which polymorphic markers co-segregate with a phenotypic trait. See, e.g., Kerem *et al.*, *Science* 245, 1073-1080 (1989); Monaco *et al.*, *Nature* 316, 842 (1985); Yamoka *et al.*, *Neurology* 40, 222-226 (1990); Rossiter *et al.*, *FASEB Journal* 5, 21-27 (1991).

- Linkage is analyzed by calculation of LOD (log of the odds) values. A lod
20 value is the relative likelihood of obtaining observed segregation data for a marker and a genetic locus when the two are located at a recombination fraction θ , versus the situation in which the two are not linked, and thus segregating independently (Thompson & Thompson, *Genetics in Medicine* (5th ed, W.B. Saunders Company, Philadelphia, 1991); Strachan, "Mapping the human genome" in *The Human*
25 *Genome* (BIOS Scientific Publishers Ltd, Oxford), Chapter 4). A series of likelihood ratios are calculated at various recombination fractions (θ), ranging from $\theta = 0.0$ (coincident loci) to $\theta = 0.50$ (unlinked). Thus, the likelihood at a given value of θ is: probability of data if loci linked at θ to probability of data if loci unlinked. The computed likelihoods are usually expressed as the \log_{10} of this ratio
30 (i.e., a lod score). For example, a lod score of 3 indicates 1000:1 odds against an apparent observed linkage being a coincidence. The use of logarithms allows data

collected from different families to be combined by simple addition. Computer programs are available for the calculation of lod scores for differing values of θ (e.g., LIPED, MLINK (Lathrop, *Proc. Nat. Acad. Sci. (USA)* 81, 3443-3446 (1984)). For any particular lod score, a recombination fraction may be determined from
5 mathematical tables. See Smith *et al.*, *Mathematical tables for research workers in human genetics* (Churchill, London, 1961); Smith, *Ann. Hum. Genet.* 32, 127-150 (1968). The value of θ at which the lod score is the highest is considered to be the best estimate of the recombination fraction.

Positive lod score values suggest that the two loci are linked, whereas
10 negative values suggest that linkage is less likely (at that value of θ) than the possibility that the two loci are unlinked. By convention, a combined lod score of +3 or greater (equivalent to greater than 1000:1 odds in favor of linkage) is considered definitive evidence that two loci are linked. Similarly, by convention, a negative lod score of -2 or less is taken as definitive evidence against linkage of the
15 two loci being compared. Negative linkage data are useful in excluding a chromosome or a segment thereof from consideration. The search focuses on the remaining non-excluded chromosomal locations.

In another embodiment, the invention relates to pharmaceutical compositions comprising a variant BDNF gene product. As used herein, a variant BDNF gene
20 product is intended to mean gene products which are encoded by the variant allele of the BDNF gene and includes, but is not limited to, the complete (uncleaved) variant BDNF gene product, the cleaved BDNF protein and the cleaved prepro portion of the gene product. In one embodiment, the gene product is a peptide comprising amino acids -1 through -132 of a variant BDNF gene product, or a functional portion
25 thereof, for use in the treatment of neuropsychiatric disorders. The invention further relates to the use of compositions (i.e., agonists) which enhance or increase the activity of a peptide comprising amino acids -1 through -132 of the variant BDNF gene product, or a functional portion thereof, for use in the treatment of neuropsychiatric disorders. The invention also relates to the use of compositions
30 (i.e., antagonists) which reduce or decrease the activity of a peptide comprising amino acids -1 through -132 of the variant BDNF gene product, or a functional

portion thereof, for use in the treatment of neuropsychiatric disorders. In a particular embodiment the neuropsychiatric disorder is bipolar disorder.

In addition to substantially full-length polypeptides expressed by variant genes, the present invention includes biologically active fragments of the polypeptides, or analogs thereof, including organic molecules which simulate the interactions of the peptides. Biologically active fragments include any portion of the full-length polypeptide which confers a biological function on the variant gene product, including ligand binding, and antibody binding. Ligand binding includes binding by nucleic acids, proteins or polypeptides, small biologically active molecules, or large cellular structures.

For instance, the variant polypeptide or protein, or fragment thereof, of the present invention can be formulated with a physiologically acceptable medium to prepare a pharmaceutical composition. The particular physiological medium may include, but is not limited to, water, buffered saline, polyols (e.g., glycerol, propylene glycol, liquid polyethylene glycol) and dextrose solutions. The optimum concentration of the active ingredient(s) in the chosen medium can be determined empirically, according to procedures well known to medicinal chemists, and will depend on the ultimate pharmaceutical formulation desired. Methods of introduction of exogenous peptides at the site of treatment include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, oral and intranasal. Other suitable methods of introduction can also include rechargeable or biodegradable devices and slow release polymeric devices. The pharmaceutical compositions of this invention can also be administered as part of a combinatorial therapy with other agents and treatment regimens.

Polyclonal and/or monoclonal antibodies that specifically bind one form of the gene product but not to the other form of the gene product are also provided. Antibodies are also provided that bind a portion of either the variant or the reference gene product that contains the polymorphic site. Antibodies can be made by injecting mice or other animals with, for example, the variant gene product or peptide fragments thereof comprising the variant portion. The peptide fragments can be synthetically produced or produced in a suitable host cell expressing a nucleic

acid encoding said peptide. In another embodiment, the animal is injected with the reference gene product or fragments thereof containing amino acid position -63. Monoclonal antibodies are screened as are described, for example, in Harlow & Lane, *Antibodies, A Laboratory Manual*, Cold Spring Harbor Press, New York
5 (1988); Goding, *Monoclonal antibodies, Principles and Practice* (2d ed.) Academic Press, New York (1986). Monoclonal antibodies are tested for specific immunoreactivity with, for example, a variant gene product and lack of immunoreactivity to the corresponding prototypical gene product. In another embodiment, antibodies are produced and tested for specific immunoreactivity to the
10 reference gene product and lack of immunoreactivity to the variant gene product. These antibodies are useful in diagnostic assays for detection of the variant form, or as an active ingredient in a pharmaceutical composition.

The invention further relates to a method of diagnosing or aiding in the diagnosis of a disorder associated with the presence of all or a portion of the prepro
15 BDNF protein in an individual. The method comprises obtaining a biological sample containing the prepro BDNF protein or relevant portion thereof from the individual and determining the amino acid present at amino acid position -63 relative to the first amino acid of the mature protein. Wherein the presence of the reference amino acid, valine at this position is indicative of increased likelihood of
20 the disorder in the individual as compared with an appropriate control, *e.g.*, an individual having the variant amino acid at position -63. In one embodiment, the prepro portion of BDNF from an individual is analyzed.

In one embodiment, the method comprises obtaining a biological sample containing the prepro BDNF protein or relevant portion thereof from the individual
25 and determining the amino acid present at position -63 relative to the first amino acid of the mature protein, wherein presence of a variant amino acid, *e.g.*, methionine, at said position is indicative of decreased likelihood of the disorder in the individual as compared with an appropriate control, *e.g.*, an individual having the reference (valine) amino acid said position. In one embodiment, the prepro
30 portion of BDNF is analyzed.

In one embodiment, the invention relates to a method for predicting the likelihood that an individual will have a bipolar disorder (or aiding in the diagnosis of a bipolar disorder), comprising the steps of obtaining a biological sample comprising the prepro BDNF protein or fragment thereof containing amino acid position -63 from an individual to be assessed and determining the amino acid present at amino acid position -63. The presence of the variant amino acid at this position indicates that the individual has a lower likelihood of having a bipolar disorder than an individual having the reference amino acid at this position, or a lower likelihood of having severe symptomology. In a particular embodiment, the individual is an individual at risk for development of bipolar disorder.

The invention also relates to a method for predicting the likelihood that an individual will have a bipolar disorder, or for aiding in the diagnosis of a bipolar disorder, or predicting the likelihood of having altered symptomology associated with a bipolar disorder, comprising the steps of obtaining a biological sample comprising prepro BDNF protein or fragment thereof containing amino acid position -63 from an individual to be assessed and determining the amino acid present at amino acid positions -63 of the prepro BDNF gene product. For example, the prepro region of the BDNF can be cleaved from or linked to the mature BDNF protein. As used herein, the term "fragment thereof" of the prepro BDNF protein is intended to encompass any portion of the protein which comprises the polymorphic amino acid position. The presence of valine at position -63 indicates that the individual has a greater likelihood of having bipolar disorder, or a greater likelihood of having severe symptomology associated with a bipolar disorder, than if that individual had a variant amino acid at this position. Conversely, the presence of methionine indicates that the individual has a reduced likelihood of having a bipolar disorder or a likelihood of having reduced symptomology associated with a bipolar disorder, than if that individual had the reference amino acid at this position.

In a particular embodiment, the individual is an individual at risk for development of a bipolar disorder. In another embodiment the individual exhibits clinical symptomology associated with a bipolar disorder. In one embodiment, the individual has been clinically diagnosed as having a bipolar disorder.

In this embodiment of the invention, the biological sample contains protein molecules from the test subject. As described above for BDNF cDNA or mRNA, suitable sources for the biological sample are any tissue or bodily fluid that is expected to express or contain prepro BDNF protein or the prepro portion of BDNF can be used. *In vitro* techniques for detection of protein of interest include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations and immunofluorescence. Furthermore, *in vivo* techniques for detection of protein include introducing into a subject a labeled anti-protein antibody. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques. Polyclonal and/or monoclonal antibodies that specifically bind to variant gene products but not to corresponding reference gene products, and vice versa, are also provided. Antibodies can be made as described above. These antibodies are useful in diagnostic assays for detection of the variant form, or as an active ingredient in a pharmaceutical composition.

The invention also encompasses kits for detecting the presence of proteins or nucleic acid molecules of the invention in a biological sample. For example, the kit can comprise a labeled compound or agent (e.g., nucleic acid probe such as SEQ ID NO: 11,) capable of detecting protein or mRNA (or cDNA produced from the mRNA) in a biological sample; means for determining the identity of nucleotide 424 of the BDNF gene in the mRNA corresponding mRNA in the sample or the amino acid identity at position -63 of the prepro portion of BDNF in the sample; and means for comparing said identities of mRNA in the sample with a suitable standard. The kit can also comprise control samples for use as standards, representing individuals homozygous for the reference or variant nucleotide in the case of analyzing nucleic acid, or the reference or variant amino acid in the case of analyzing proteins, or representing a heterozygous individual. For the detection of the reference or the variant prepro portion of BDNF, the kit can contain antibodies specific for either the reference or the variant prepro portion of BDNF together with suitable reagents to detect antibody binding to its target antigen. The compound or agent can be

packaged in a suitable container. The kit can further comprise instructions for using the kit to detect protein or nucleic acid.

The invention further pertains to compositions, e.g., vectors, comprising a nucleotide sequence encoding variant BDNF gene product. In one embodiment, the gene product is a peptide comprising amino acids -1 through -132 of the variant BDNF gene product, or a functional portion thereof, for use in the treatment of neuropsychiatric disorders. For example, variant genes can be expressed in an expression vector in which a variant gene is operably linked to a native or other promoter. Usually, the promoter is a eukaryotic promoter for expression in a mammalian cell. The transcription regulation sequences typically include a heterologous promoter and optionally an enhancer which is recognized by the host. The selection of an appropriate promoter, for example trp, lac, phage promoters, glycolytic enzyme promoters and tRNA promoters, depends on the host selected. Commercially available expression vectors can be used. Vectors can include host-recognized replication systems, amplifiable genes, selectable markers, host sequences useful for insertion into the host genome, and the like.

The means of introducing the expression construct into a host cell varies depending upon the particular construction and the target host. Suitable means include fusion, conjugation, transfection, transduction, electroporation or injection, as described in Sambrook, *supra*. A wide variety of host cells can be employed for expression of the variant gene, both prokaryotic and eukaryotic. Suitable host cells include bacteria such as *E. coli*, yeast, filamentous fungi, insect cells, mammalian cells, typically immortalized, e.g., mouse, CHO, human and monkey cell lines and derivatives thereof. Preferred host cells are able to process the variant gene product to produce an appropriate mature polypeptide. Processing includes glycosylation, ubiquitination, disulfide bond formation, general post-translational modification, and the like.

It is also contemplated that cells can be engineered to express the variant BDNF allele of the invention by gene therapy methods. For example, DNA encoding the variant BDNF gene product, or an active fragment or derivative thereof, can be introduced into an expression vector, such as a viral vector, and the

vector can be introduced into appropriate cells in an animal. In such a method, the cell population can be engineered to inducibly or constitutively express active variant BDNF gene product. In a preferred embodiment, the vector is delivered to the bone marrow, for example as described in Corey *et al.* (*Science* 244:1275-1281
5 (1989)).

The invention further provides transgenic nonhuman animals capable of expressing an exogenous variant BDNF gene and/or having one or both alleles of an endogenous variant BDNF gene inactivated. Expression of an exogenous variant gene is usually achieved by operably linking the gene to a promoter and optionally
10 an enhancer, and microinjecting the construct into a zygote. See Hogan *et al.*, "Manipulating the Mouse Embryo, A Laboratory Manual," Cold Spring Harbor Laboratory. Inactivation of endogenous variant genes can be achieved by forming a transgene in which a cloned variant gene is inactivated by insertion of a positive selection marker. See Capecchi, *Science* 244, 1288-1292 (1989). The transgene is
15 then introduced into an embryonic stem cell, where it undergoes homologous recombination with an endogenous variant gene. Mice and other rodents are preferred animals. Such animals provide useful drug screening systems.

The invention will be further illustrated by the following non-limiting examples. The teachings of the references cited herein are incorporated herein by
20 reference in their entirety.

EXAMPLES

Sample Population

A sample population of 150 trios was initially assessed by genotyping methods for heterozygosity with respect to the BDNF reference and variant alleles as
25 described herein. A trio included two parents and an offspring diagnosed as having bipolar disorder according to the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders. Of the 150 trios assessed, 98 of these trios had at least one parent who was heterozygous for the BDNF reference and variant alleles; these 98 trios were selected for further study, as the heterozygosity of the
30 parent allowed a determination of which allele the parent transmitted to the bipolar offspring. The bipolar offspring in the trios were assessed by genotyping methods to

determine which BDNF allele had been transmitted to them by the heterozygous parent. In instances where two parents had two offspring diagnosed with bipolar disorder, each trio (i.e., two parents and one offspring) was considered individually.

SBE-FRET Protocol

- 5 The genotyping method used for these studies was based on single-base extension (SBE) and fluorescence resonance energy transfer (FRET). A locus-specific primer (FRET primer; 5'-GGCTGACACTTTTCGAACAC (SEQ ID NO: 11) was ordered 5' labeled with FAM. The primer was designed so that the 3' end was one base 5' to the polymorphic site of interest (e.g., nucleotide 424). The locus of
10 interest was amplified and single base extension of the FRET primer was performed with fluorescently labeled ddNTPs in dye-terminator sequencing fashion, except that no deoxyribonucleotides are present. PCR primers were:

Forward PCR primer 5'-TGTAACGACGGCCAGTCTTGACATCA
TTGGCTGACACT (SEQ ID NO: 12); and

- 15 Reverse PCR primer 5'-TAATACGACTCACTATAGGGGTACAAGT
CTGCGTCCTTATTGTTT (SEQ ID NO: 13).

- The ddNTP corresponding to the variant base (A) was labeled with TAMRA, and the reference base (G) was labeled with ROX. Depending on the genotype of the individual, the FRET primer was extended with a ROX-labeled or TAMRA-labeled
20 ddNTP. Upon incorporation of either ROX- or TAMRA-labeled ddNTPs, energy transfer occurs between the donor dye (FAM on FRET primer) and the acceptor dye (the ROX- or TAMRA-labeled ddNTP). An increase in the fluorescence intensity of one (for a homozygote) or both (for a heterozygote) of the acceptor dyes was used to infer the genotype of an individual.

- 25 Summary of experimental procedures used in the above-described analysis.

- I Amplify locus of interest
- II Clean-up of PCR products with shrimp alkaline phosphate (SAP) and Exonuclease I (EXO)
- III Single-base extension/fluorescence detection in ABI7700

I Amplification of locus of interest - for 96-well plate

TABLE I: PCR MIX

	Each Reaction (μ L)	For 96-well plage (μ L)
10 mM dNTP	0.05	5.2
10X PCRII buffer	2.0	208
25 mM MgCl ₂	1.2	125
20 μ M PCR primer F	0.25	26
20 μ M PCR primer R	0.25	26
ddH ₂ O	11.05	1149
5 U/ μ L Amplitaq-gold	<u>0.2</u>	20.8
	15	

- 10 Fifteen microliters of the PCR mix were added to a 96-well MJ plate. Five microliters of genomic DNA (5 ng/ μ L) were added to the aliquoted PCR mix. (5 μ L of 1 ng/ μ L is often adequate).

The plate was sealed with MJ plate-seal 'A'.

PCR was conducted using the following program:

- 15 96°C x 10 minutes
 96°C x 30 seconds, 50C x 1 minute, 72C x 1 minute for 35 cycles
 72°C x 10 minutes followed by a hold at 4°C

II PCR product clean-up

TABLE II: SAP/EXO MIX

	Each reaction (μL)	For 96-well plate (μL)
5 Shrimp alkaline phosphatase (1U/ μL)	1.0	104
Exonuclease 1 (10 U/ μL)	0.05	5.2
10X SAP buffer	1.0	104
ddH ₂ O	<u>2.95</u>	306.8
	5.0	

Five microliters of SAP/EXO mix were added to a clean MJ plate. Five microliters
10 of the PCR product were added directly to the aliquoted SAP/EXP mix. The PCR
plates were spun down and sealed with Microseal A film. The mixture was
incubated at 37°C for 45 minutes and then at 96°C for 15 minutes.

III Single-base extension/fluorescence detection in ABI7700

(The reactions were carried out in the same MJ plate used for SAP/EXO step, capped with 8-strip MicroAmp optical caps)

The ddNTPs that should be incorporated in the genotyping reaction were selected.

- 5 In this experiment, TAMRA was used to identify the variant base and ROX for the reference base, although other possibilities exist.

TABLE IV: SBE-FRET MIX

	Each reaction (μL)	For 96-well plate (μL)
FAM primer (100 μM)	0.02	2.08
ROX ddNTP (100 μM)	0.02	2.08
10 TAMRA ddNTP (100 μM)	0.02	2.08
Thermoseq. Buffer (10x)	2.0	208
ddH ₂ O	7.9	821.6
Thermosequenase (32 U/ μL)	<u>0.016</u>	1.7
	10.0	

- 15 • Ten microliters of SBE-FRET mix were added to the MJ plates containing 10 μL SAP/Exo treated PCR products.
- The plates were tapped on bench to mix, they can also be spun briefly if necessary.
- The wells were capped with optical caps. The capped wells can be rolled with roller if necessary.
- 20 • The plates were placed in a thermocycling detector apparatus (ABI7700).
- The plates were incubated for 6 cycles of (for a 20 μL reaction) as follows:
- 96°C x 15 seconds
- 50°C x 30 seconds
- 25 60°C x 30 seconds

Data were collected in the 60°C stage using detection settings suitable for measuring TAMRA and ROX fluorescence.

At the end of the run, the plate was saved as "projectname.SBExxx.pyyy", where project name is the project (e.g. cancer), xxx is the number of the
5 polymorphism being genotyped (e.g. 48), and yyy is the plate number (e.g. 04).

To analyze the data, "analyze" was selected under the Analysis menu (command-L). The 7700 apparatus provides a screen to adjust the threshold levels. "0" was input in the "use threshold" box and "2" for cycle number in both the Baseline start and stop boxes. "Update calculations" was selected. The resulting
10 error message box was closed.

The data were exported and analyzed using Excel.

Data were analyzed by plotting ROX fluorescence versus TAMRA fluorescence and comparing the values between samples, control samples containing no template and samples of known genotype. Typically, homozygous reference
15 controls have little or no TAMRA fluorescence, homozygous variant controls have little or no ROX fluorescence and heterozygous controls have similar TAMRA and ROX fluorescence. Genotypes determined included REF, HET, VAR, FAIL (signal too low) or A-FAIL (ambiguous - signal not within one of the values set above)

Results

20 Data from the work described herein has shown that there is a variation from random (i.e., that which would be expected by chance) in the transmission of the reference (G) and variant (A) alleles from an individual parent who is heterozygous for the BDNF alleles to an offspring diagnosed with bipolar disorder. Figure 2 shows data resulting from a genotyping assessment of the reference and variant
25 alleles of BDNF in a group of trios having one or more bipolar offspring. Column 1 shows the family reference number for the trio. Column 2 shows the reference number for the individual being assessed. Columns 3 and 4 show the reference number for the father and the mother, respectively, in the trio. Column 5 shows the gender of the individual being assessed. Column 6 shows the genotype of the
30 individual being assessed with respect to BDNF; REF indicates that the individual

was homozygous for the reference (G) allele, VAR indicates that the individual was homozygous for the variant allele, HET indicates that the individual was heterozygous, and FAIL indicates that no data was collected for that individual. Columns 7 and 8 show the number of times that the reference and variant allele, respectively, were transmitted to offspring by the heterozygous parent.

Figure 3 shows data resulting from a genotyping assessment of the reference and variant alleles of BDNF in an additional group of trios having one or more bipolar offspring. Column 1 shows the family reference number for the trio. Column 2 shows the individual reference number for the individual being assessed. Column 3 shows whether the individual being assessed was the offspring (patient) or parent. Column 4 shows the genotype of the individual being assessed with respect to BDNF; REF indicates that the individual was homozygous for the reference (G) allele, VAR indicates that the individual was homozygous for the variant allele, HET indicates that the individual was heterozygous, and FAIL indicates that no data was collected for that individual. Columns 5 and 6 show the number of times that the reference and variant allele, respectively, were transmitted to offspring by the heterozygous parent.

The data demonstrate that the variant allele (A) is transmitted less frequently (34 of 98 times) to the bipolar offspring than would be expected by chance, while the reference allele (G) is transmitted more frequently (64 of 98 times) than would be expected by chance ($p=0.004$). In the general population (in which about 0.8 percent of the individuals are diagnosed with bipolar disorder), the variant (A) allele occurs with a frequency of 15 percent, while the reference allele occurs with a frequency of 85 percent. In the sample population assessed as described herein, in which all of the individuals are diagnosed with bipolar disorder, the variant allele occurs with a frequency of 7 percent. Thus, it appears that the variant allele may contribute to protection or reduction in symptomology with respect to bipolar disorder.

Figure 4 and Table V show data obtained from additional human samples.

TABLE V

Samples	Trans	Untrans.	p val	# trans	relative risk	95% CF	# trios
Hopkins	55	29	0.0023	84	1.90	1.25-3.0	127
U01 + NIMH	50	42	0.2021	92	1.19	0.83-1.8	155
British	38	32	0.2366	70	1.19	0.77-1.8	145
all repl.	88	74	0.1357	162	1.19	0.91-1.8	300
all BP	143	103	0.0054	246	1.39	1.1-1.8	427

“Hopkins” refers to a to a group of patients with bipolar disorder obtained in
 10 collaboration with Johns Hopkins. “U01 and NIMH” refer to a group of 155 trios
 some of which are from Johns Hopkins and some are from the Genetics Initiative at
 the NIMH. “British” refers to 145 trios from 5 collaborators in England.

In Table V, “Trans” is the number of times the allele in question (in this case
 the reference allele) was transmitted from a heterozygous parents to a bipolar child.
 15 “Untrans” is the number of times the other (variant) allele was passed from the
 heterozygous parent to the bipolar child. The number of trios used is show in the
 column labeled “#trios” and is the number of trios for which genotypes were
 available. Not all of the parents were considered to be “informative”. To be
 included in the analysis, the parent in question had to be a heterozygote.

20 The relative risk (estimated relative risk on Figure 4) is defined as the
 transmission ratio in trios (i.e # transmitted alleles/# untransmitted alleles). Under a
 multiplicative disease model, this is an estimator of genotypic relative risk. The
 confidence interval was calculated using a binomial distribution.

While this invention has been particularly shown and described with
 25 references to preferred embodiments thereof, it will be understood by those skilled
 in the art that various changes in form and details may be made therein without
 departing from the scope of the invention encompassed by the appended claims.

CLAIMS

What is claimed is:

1. A method for predicting the likelihood that an individual will have a neuropsychiatric disorder, comprising the steps of:
 - 5 a) obtaining a DNA sample from an individual to be assessed; and
 - b) determining the nucleotide present at nucleotide position 424 of the brain-derived neurotrophic factor (BDNF) gene,wherein the presence of an "A" at position 424 indicates that the individual has a lower likelihood of having a neuropsychiatric disorder than an
10 individual having a "G" at that position.
2. A method according to Claim 1, wherein the neuropsychiatric disorder is bipolar disorder.
3. A method according to Claim 1, wherein the individual is an individual at risk for development of bipolar disorder.
- 15 4. A method for predicting the likelihood that an individual will have reduced symptomology associated with a neuropsychiatric disorder, comprising the steps of:
 - a) obtaining a DNA sample from an individual to be assessed; and
 - b) determining the nucleotide present at nucleotide position 424 of the
20 brain-derived neurotrophic factor (BDNF) gene,

wherein the presence of an "A" at position 424 indicates that the individual has a greater likelihood of having reduced symptomology associated with a neuropsychiatric disorder than an individual having a "G" at that position.

- 5 5. A method according to Claim 4, wherein the neuropsychiatric disorder is bipolar disorder.
6. A pharmaceutical composition comprising a peptide comprising amino acids -1 through -132, or a functional portion thereof, of variant brain-derived neurotrophic factor gene product for use in the treatment of neuropsychiatric disorders.
- 10 7. A composition according to Claim 6, wherein the neuropsychiatric disorder is bipolar disorder.
8. A method of treating a neuropsychiatric disorder, comprising administering to an individual in need thereof a pharmaceutical composition comprising a peptide comprising amino acids -1 through -132, or a functional portion
15 thereof, of variant brain-derived neurotrophic factor gene product.
9. A method according to Claim 8, wherein the neuropsychiatric disorder is bipolar disorder.
10. A pharmaceutical composition comprising a nucleic acid molecule encoding a peptide comprising amino acids -1 through -132, or a functional portion
20 thereof, of variant brain-derived neurotrophic factor gene product for use in the treatment of neuropsychiatric disorders.

11. A composition according to Claim 10, wherein the neuropsychiatric disorder is bipolar disorder.
12. A method of treating a neuropsychiatric disorder, comprising administering to an individual in need thereof a pharmaceutical composition comprising a nucleic acid molecule encoding a peptide comprising amino acids -1 through -132, or a functional portion thereof, of variant brain-derived neurotrophic factor gene product.
13. A method according to Claim 12, wherein the neuropsychiatric disorder is bipolar disorder.
- 10 14. A method for predicting the likelihood that an individual will have a neuropsychiatric disorder, comprising the steps of:
 - a) obtaining a sample from an individual to be assessed, wherein the sample comprised prepro BDNF or fragment thereof, wherein said fragment comprises amino acid -63 of prepro BDNF protein; and
 - 15 b) determining the amino acid present at amino acid -63 of said prepro BDNF,

wherein the presence of an methionine at position -63 indicates that the individual has a lower likelihood of having a neuropsychiatric disorder than an individual having a valine at that position.
- 20 15. A method according to Claim 14, wherein the determination of the amino acid at position -63 comprises contacting the sample with an antibody specific for the reference amino acid.

16. A method according to Claim 14, wherein the determination of the amino acid at position -63 comprises contacting the sample with an antibody specific for the variant amino acid.
17. A method according to Claim 14, wherein the neuropsychiatric disorder is bipolar disorder.
18. A method according to Claim 14, wherein the individual is an individual at risk for development of bipolar disorder.
19. A method for predicting the likelihood that an individual will have reduced symptomology associated with a neuropsychiatric disorder, comprising the steps of:
- a) obtaining a sample from an individual to be assessed, wherein the sample comprised prepro BDNF or fragment thereof, wherein said fragment comprises amino acid -63 of prepro BDNF protein; and
 - b) determining the amino acid present at amino acid -63 of said prepro BDNF,
- wherein the presence of an methionine at position -63 indicates that the individual has a greater likelihood of having reduced symptomology associated with a neuropsychiatric disorder than an individual having a valine at that position.
20. A method according to Claim 19, wherein the determination of the amino acid at position -63 comprises contacting the sample with an antibody specific for the reference amino acid.

21. A method according to Claim 19, wherein the determination of the amino acid at position -63 comprises contacting the sample with an antibody specific for the variant amino acid.
22. A method according to Claim 19, wherein the neuropsychiatric disorder is bipolar disorder.
23. A kit comprising;
- a) an SBE-FRET primer, wherein said primer comprises SEQ ID NO: 11; and
- b) control nucleic acid samples representing the genotype of at least one of the group consisting of: an individual homozygous for a "A" at nucleotide position 424 of a BDNF gene, an individual homozygous for a "G" at nucleotide position 424 of a BDNF gene and an individual heterozygous for said position.
24. A kit comprising;
- a) at least one antibody, selected from the group consisting of: an antibody specific for a prepro portion or fragment thereof of BDNF protein, wherein said prepro portion or fragment there comprises a methionine at amino acid position -63 and an antibody specific for a prepro portion or fragment thereof of BDNF protein, wherein said prepro portion or fragment thereof comprises a valine at amino acid position -63, and
- b) control protein samples representing the genotype of at least one of the group consisting of: an individual homozygous for a nucleic acid sequence encoding a methionine amino acid position -63 of prepro BDNF protein, an individual homozygous for a nucleic acid sequence

encoding a valine at amino acid position -63 of prepro BDNF protein and an individual heterozygous for said position.

```

hB (G) 1  ATTTAAAC  CACATACAGCACACTACTGA  CACTGATTGTGTCTGGTGC  AG →
hB (C) 1  .....
rB (G) 1
rB (C)
mB (C) 1
pB (C) 1                                     AAACCGGG

```

→hB (G) CTGGAGTTTATCACTAAG ACATAAAAAAACCTTGACCC TGCAGAATGGCCTGGAATTA CAATCAGATGGGCCACATG→
hB (C)
rB (G)AAAAA.GAA A.A.A..A..T...A..... ..G.....-.....
rB (C)
mB (C)
dB (C) CACCAAAGATTCCCCCCT ACCCCTTCTTTTGACCAAA GGGAACTGAAAAAATAATA GAGTCTGGGGATTTCGGGG

												SPICE											
												Pro	Val	Phe	Cys	Leu	Val	Ser	Ala	Phe	Ser	Leu	Gln
→hB (G)	G	CATCCCGGTGAAAGAAAGCCC	<u>TAA</u>	CCA	GTT	TTC	TGT	CTT	GTT	TCT	GCT	TTC	TCC	CTA	<u>CAG</u>								
hB (C)																					
rB (G)	.	TG....CAA..... <u>T</u> ..GT.		..T		C.G			..C			..C		..T	..C								
rB (C)		CGCCTTGGACAG	AGC	CAG	CGG	ATT	TGT	CCG	AGG	TGG	<u>TAG</u>	TAC	TTC	ATC									
mB (C)		GTCTTCCCCAGAGCAGC	TGC	CTT	GAT	GTT	TAC	TTT	GAC	AAG	<u>TAG</u>	<u>TGA</u>	CTG	AAA	A..								
pB (C)	C	CGAAGTCTTCCCCAGAGCAGC	TGC	CTT	GAT	GTT	TAC	TTT	GAC	AAG	TAG	TGA	CTG	AAA	A..								

[illegible][illegible][illegible]

					-80											
	Val	Asn	Gly	Pro	Lys	Ala	Gly	Ser	Arg	Gly	Leu	Thr	---			
→hB(C)364	GTG	AAT	GGG	CCC	AAG	GCA	GGT	TCA	AGA	GGC	TTG	ACA	---			→
					Arg								Thr			
rB(C)208G.GT	C..	..G	ACG			
					Arg								Thr			
mB(C)213G.GT	C..	..G	ACG			
													Ser			
pB(C)303	C..	...	TCG			

[illegible]

Fig. 1A

[illegible]

3/16

Fam.	Individual	FID	MID	Sex	BONFU1	REF	VAR
3	003-001	3008	3007	F	A-FAIL		
3	003-007	0	0	F	REF		
3	003-005	0	0	M	REF		
9	009-001	9007	9006	M	REF		
9	009-005	9007	9006	M	REF		
9	009-006	0	0	F	HET	2	0
9	009-007	0	0	M	REF		
11	011-002	11005	11006	F	HET		
11	011-005	0	0	M	REF		
11	011-006	0	0	F	HET	0	2
11	011-001	11005	11006	F	HET		
12	012-001	12006	12005	M	REF		
12	012-003	12006	12005	M	REF		
12	012-005	0	0	F	REF		
12	012-006	0	0	M	REF		
14	014-002	14006	14004	F	REF		
14	014-004	0	0	F	REF		
14	014-006	0	0	M	HET	1	1
14	014-001	14006	14004	M	HET		
15	015-001	15010	15011	M	REF		
15	015-002	15010	15011	F	REF		
15	015-010	0	0	M	REF		
15	015-011	0	0	F	REF		
22	022-005	22010	22007	M	REF		
22	022-007	0	0	F	REF		
22	022-010	0	0	M	REF		
22	022-001	22010	22007	M	REF		
24	024-001	24005	24006	M	VAR		
24	024-002	24005	24006	F	VAR		
24	024-005	0	0	M	HET	0	2
24	024-006	0	0	F	VAR		
27	027-003	27005	27008	M	REF		
27	027-005	0	0	M	REF		
27	027-008	0	0	F	REF		

Fig. 2A

SUBSTITUTE SHEET (RULE 26)

Fam.	Individual	FID	MID	Sex	BONFU1	REF	VAR
27	027-001	27005	27008	M	REF		
30	030-001	30007	30008	M	REF		
30	030-002	30007	30008	F	REF		
30	030-007	0	0	M	REF		
30	030-008	0	0	F	REF		
39	039-012	0	0	M	HET	2	0
39	039-026	39012	39004	M	HET		
39	039-027	39012	39004	F	HET		
39	039-004	0	0	F	VAR		
45	045-003	45006	45007	M	HET		
45	045-004	45006	45007	M	REF		
45	045-006	0	0	M	HET	1	1
45	045-007	0	0	F	REF		
57	057-002	0	0	F	REF		
57	057-004	57001	57002	F	HET		
57	057-001	0	0	M	HET	0	1
58	058-001	58010	58011	M	HET		
58	058-004	58010	58011	M	HET		
58	058-010	0	0	M	HET	1	1
58	058-011	0	0	F	HET	1	1
61	061-014	0	0	M	REF		
61	061-015	0	0	F	HET	2	0
61	061-001	61014	61015	F	HET		
61	061-007	61014	61015	F	HET		
63	063-001	63010	63011	F	HET		
63	063-003	63010	63011	M	HET		
63	063-010	0	0	M	REF		
63	063-011	0	0	F	HET	0	2
64	064-026	0	0	M	REF		
64	064-027	0	0	F	REF		
64	064-001	64026	64027	F	REF		
64	064-002	64026	64027	M	REF		
65	065-001	0	0	M	REF		

Fig. 2B

5/16

Fam	Individual	FID	MID	Sex	BONFU1	REF	VAR
65	065-006	0	0	F	REF		
65	065-014	65001	65006	M	REF		
65	065-015	65001	65006	M	REF		
74	074-014	0	0	M	HET	2	0
74	074-015	0	0	F	REF		
74	074-001	74014	74015	F	REF		
74	074-005	74014	74015	F	HET		
75	075-001	75005	75006	M	REF		
75	075-002	75005	75006	M	REF		
75	075-005	0	0	M	HET	2	0
75	075-006	0	0	F	REF		
79	079-011	0	0	M	HET	1	1
79	079-013	0	0	F	REF		
79	079-001	79011	79013	F	HET		
79	079-002	79011	79013	F	REF		
84	084-006	84011	84012	F	REF		
84	084-011	0	0	M	REF		
84	084-012	0	0	F	REF		
87	087-001	87006	87005	F	REF		
87	087-005	0	0	F	REF		
87	087-006	0	0	M	REF		
92	092-001	92004	92005	F	REF		
92	092-004	0	0	M	REF		
92	092-005	0	0	F	REF		
93	093-001	93015	93016	F	REF		
93	093-015	0	0	M	HET	1	0
93	093-016	0	0	F	HET	1	0
94	094-001	94004	94005	F	REF		
94	094-004	0	0	M	REF		
94	094-005	0	0	F	REF		
95	095-001	95012	95013	F	REF		
95	095-007	95012	95013	M	REF		
95	095-013	0	0	F	FAIL		

Fig. 2C

SUBSTITUTE SHEET (RULE 26)

6/16

Fam	Individual	FID	MID	Sex	BONFUI	REF	VAR
97	097-001	97012	97013	F	HET		
97	097-012	0	0	M	REF		
97	097-013	0	0	F	VAR		
100	100-001	100014	100015	F	REF		
100	100-005	100014	100015	F	REF		
100	100-014	0	0	M	REF		
100	100-015	0	0	F	HET	2	C
108	108-011	0	0	M	HET	1	0
108	108-020	0	0	F	REF		
108	108-001	108011	108020	F	REF		
109	109-001	109015	109017	F	REF		
109	109-004	109015	109017	F	REF		
109	109-015	0	0	M	REF		
109	109-017	0	0	F	REF		
111	111-004	0	0	M	REF		
111	111-008	0	0	F	HET	1	1
111	111-001	111004	111008	F	HET		
111	111-002	111004	111008	F	REF		
112	112-001	112012	112008	F	REF		
112	112-004	112012	112008	F	REF		
112	112-006	0	0	F	REF		
113	113-016	0	0	F	REF		
113	113-001	113005	113018	M	REF		
113	113-002	113005	113018	M	REF		
113	113-005	0	0	M	REF		
114	114-001	114005	114010	M	VAR		
114	114-003	114005	114010	M	HET		
114	114-010	0	0	F	HET	0	1
115	115-001	115007	115011	F	HET		
115	115-004	115007	115011	F	HET		
115	115-007	0	0	M	HET	1	1

Fig. 2D

7/16

Fam	Individual	FID	MID	Sex	BONFUL	REF	VAR
115	115-011	0	0	F	HET	1	1
116	116-001	116007	116008	F	A-FAIL		
116	116-004	116007	116008	M	FAIL		
116	116-007	0	0	M	REF		
116	116-008	0	0	F	HET	1	0
117	117-001	117006	117007	M	REF		
117	117-005	117006	117007	F	REF		
117	117-007	0	0	F	HET	2	0
118	118-002	118005	118010	F	HET		
118	118-005	0	0	M	REF		
118	118-010	0	0	F	HET	1	1
118	118-001	118005	118010	F	REF		
121	121-001	121008	121009	F	REF		
121	121-002	121008	121009	M	REF		
121	121-008	0	0	M	REF		
121	121-009	0	0	F	REF		

Fig. 2E

8/16

Fam	Individual	FID	MID	Sex	BONFUL	REF	VAR
122	122-002	122005	122006	F	REF		
122	122-003	0	0	M	HET	2	0
122	122-006	0	0	F	HET	1	1
122	122-001	122005	122006	M	HET		
123	123-001	123007	123014	F	REF		
123	123-004	123007	123014	F	REF		
123	123-007	0	0	M	REF		
123	123-014	0	0	F	REF		
124	124-034	0	0	M	HET	1	1
124	124-035	124034	124001	M	REF		
124	124-036	124034	124001	M	HET		
124	124-001	0	0	F	REF		
125	125-001	0	0		REF		
125	125-005	0	0		HET	1	0
125	125-012	0	0		REF		
128	128-014	0	0	F	REF		
128	128-001	128006	128014	F	REF		
128	128-002	128006	128014	F	REF		
132	132-001	132006	132007	M	HET		
132	132-005	132006	132007	F	REF		
132	132-006	0	0	M	REF		
132	132-007	0	0	F	HET	1	1
200	200-001	200008	200009	M	HET		
200	200-008	0	0	M	VAR		
200	200-009	0	0	F	REF		
202	202-001	202007	202008	F	REF		
202	202-007	0	0	M	REF		
202	202-008	0	0	F	REF		
203	203-001	203004	203005	M	REF		
203	203-002	203004	203005	F	HET		
203	203-004	0	0	M	HET	1	1
203	203-005	0	0	F	HET	2	0
204	204-006	0	0	M	REF		

Fig. 2F

SUBSTITUTE SHEET (RULE 26)

9/16

Fam	Individual	FID	MID	Sex	BONFUL	REF	VAR
204	204-007	0	0	F	REF		
204	204-001	204006	204007	F	REF		
206	206-001	206011	206006	M	REF		
206	206-006	0	0	F	REF		
206	206-011	0	0	M	REF		
210	210-001	210008	210009	M	HET		
210	210-008	0	0	M	REF		
210	210-009	0	0	F	VAR		
211	211-001	211004	211005	F	HET		
211	211-004	0	0	M	HET	1	0
211	211-005	0	0	F	HET	0	1
217	217-002	217005	217006	M	HET		
217	217-005	0	0	M	HET	1	1
217	217-006	0	0	F	HET	2	0
217	217-001	217005	217006	F	REF		
228	228-001	228004	228005	F	HET		
228	228-004	0	0	M	HET	1	0
228	228-005	0	0	F	VAR		
229	229-006	0	0	F	REF		
229	229-001	229005	229006	F	REF		
229	229-005	0	0	M	REF		
231	231-001	231008	231009	F	HET		
231	231-002	231008	231009	F	HET		
231	231-008	0	0	M	HET	1	1
231	231-009	0	0	F	HET	1	1
233	233-008	0	0	F	REF		
233	233-001	233007	233008	F	REF		
233	233-002	233007	233008	M	REF		
233	233-007	0	0	M	HET	2	0
236	236-001	236014	236015	F	REF		
236	236-002	236014	236015	M	REF		
236	236-014	0	0	M	REF		
236	236-015	0	0	F	REF		

Fig. 2G

10/16

Fam	Individual	FID	MID	Sex	BONFU1	REF	VAR
239	239-007	0	0	F	REF		
239	239-001	239006	239007	M	REF		
239	239-003	239006	239007	F	HET		
239	239-006	0	0	M	HET	1	1
240	240-001	240005	240006	F	HET		
240	240-002	240005	240006	F	HET		
240	240-005	0	0	M	VAR		
240	240-006	0	0	F	REF		
251	251-011	0	0	F	REF		
251	251-001	251010	251011	M	REF		
251	251-006	251010	251011	M	REF		
251	251-010	0	0	M	REF		
252	252-001	252008	252009	F	HET		
252	252-005	252008	252009	F	REF		
252	252-009	0	0	F	HET	1	0
257	257-001	257003	257004	F	REF		
257	257-002	257003	257004	M	REF		
257	257-003	0	0	M	REF		
257	257-004	0	0	F	REF		
260	260-001	260007	260008	F	REF		
260	260-002	260007	260008	F	REF		
260	260-007	0	0	M	REF		
260	260-008	0	0	F	REF		
263	263-001	263005	263006	F	REF		
263	263-003	263005	263006	F	REF		
263	263-005	0	0	M	REF		
263	263-006	0	0	F	REF		
266	266-001	266010	266011	F	REF		
266	266-004	266010	266011	F	REF		
266	266-010	0	0	M	HET	2	0
266	266-011	0	0	F	REF		
267	267-001	267004	267005	F	REF		

Fig. 2H

11/16

Fam.	Individual	FID	MID	Sex	BONFU1	REF	VAR
267	267-003	267004	267005	M	REF		
267	267-004	0	0	M	REF		
267	267-005	0	0	F	REF		
300	300-001	300004	300005	F	REF		
300	300-004	0	0	M	HET	1	0
300	300-005	0	0	F	REF		
301	301-001	301012	301013	F	HET		
301	301-008	301012	301013	M	REF		
301	301-012	0	0	M	HET	1	1
301	301-013	0	0	F	REF		
302	302-002	302009	302010	F	HET		
302	302-009	0	0	M	REF		
302	302-010	0	0	F	HET	1	1
302	302-001	302009	302010	F	REF		
303	303-001	303009	303010	M	REF		
303	303-006	303009	303010	F	REF		
303	303-009	0	0	M	REF		
303	303-010	0	0	F	REF		
304	304-004	304008	304009	F	HET		
304	304-008	0	0	M	HET	0	2
304	304-009	0	0	F	REF		
304	304-001	304008	304009	M	HET		
305	305-001	305010	305011	M	REF		
305	305-002	305010	305011	F	REF		
305	305-010	0	0	M	HET	2	0
305	305-011	0	0	F	REF		
308	308-003	0	0	M	REF		
308	308-004	0	0	F	VAR		
308	308-001	308003	308004	F	HET		
403	403-001	403004	403005	F	REF		
403	403-004	0	0	M	REF		
403	403-005	0	0	F	REF		
					REF		

Fig. 2I

SUBSTITUTE SHEET (RULE 26)

12/16

Fam	Individual	FID	MID	Sex	BONFUL	REF	VAR
					HET		
					VAR		
					NTC		
					REF		
					HET		
					VAR		
					NTC		
					HET		
					VAR		
					NTC		
						54	30
					585714		
					001766		

Fig. 2J

Fam	Individual	Status	SBEFRET	GeREF	VAR
401	401-001	parent	A-FAIL		
401	401-005	parent	REF		
401	401-006	parent	REF		
403	403-001	parent	REF		
403	403-004	parent	REF		
403	403-005	parent	REF		
404	404-007	parent	HET	1	0
404	404-001	parent	REF		
404	404-006	parent	REF		
407	407-001	parent	HET		
407	407-004	parent	HET	0	1
407	407-005	parent	REF		
408	408-001	parent	REF		
408	408-008	parent	HET	1	0
408	408-009	parent	HET	1	0
409	409-003	parent	REF		
409	409-004	parent	HET	1	0
409	409-001	parent	REF		
410	410-001	parent	HET		
410	410-003	parent	HET	0	1
410	410-004	parent	REF		
412	412-001	parent	REF		
412	412-009	parent	REF		
412	412-010	parent	REF		
414	414-001	parent	REF		
414	414-006	parent	REF		
414	414-007	parent	HET	1	0
415	415-001	parent	HET		
415	415-004	parent	REF		
415	415-005	parent	HET	0	1
417	417-005	parent	REF		
417	417-001	parent	REF		
417	417-004	parent	REF		

Fig. 3A

SUBSTITUTE SHEET (RULE 26)

Fam	Individual	Status	SSEFRET	GeREF	VAR
421	421-001	parent	VAR		
421	421-004	parent	VAR		
421	421-005	parent	VAR		
422	422-001	parent	REF		
422	422-004	parent	REF		
422	422-005	parent	HET	1	0
425	425-005	parent	REF		
425	425-006	parent	REF		
425	425-001	parent	REF		
426	426-001	parent	REF		
426	426-005	parent	REF		
426	426-006	parent	REF		
428	428-001	parent	REF		
428	428-004	parent	REF		
428	428-005	parent	REF		
430	430-001	parent	REF		
430	430-003	parent	REF		
430	430-004	parent	REF		
435	435-001	parent	REF		
435	435-003	parent	HET	1	0
435	435-004	parent	REF		
437	437-006	parent	HET	1	0
437	437-001	parent	REF		
437	437-005	parent	REF		
442	442-001	parent	HET		
442	442-004	parent	VAR		
442	442-005	parent	REF		
444	444-008	parent	REF		
444	444-009	parent	HET	0	1
444	444-010	parent	HET		
447	447-004	parent	REF		
447	447-005	parent	HET	1	0
447	447-001	parent	REF		

Fig. 3B

SUBSTITUTE SHEET (RULE 26)




FIG. 4

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
15 February 2001 (15.02.2001)

PCT

(10) International Publication Number
WO 01/11085 A3

(51) International Patent Classification⁷: **C12Q 1/68**,
A61K 38/18, A61P 25/18, A61K 48/00, G01N 33/53,
33/68

(21) International Application Number: PCT/US00/21859

(22) International Filing Date: 11 August 2000 (11.08.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/148,389 11 August 1999 (11.08.1999) US

(71) Applicant (for all designated States except US): **WHITE-
HEAD INSTITUTE FOR BIOMEDICAL RESEARCH**
[US/US]; Nine Cambridge Center, Cambridge, MA 02142
(US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **SKLAR, Pamela**
[US/US]; 68 Fuller Street, Brookline, MA 02446 (US).
LANDER, Eric, S. [US/US]; 151 Bishop Allen Drive,
Cambridge, MA 02139 (US).

(74) Agents: **HOGLE, Doreen, M. et al.**; Hamilton, Brook,
Smith & Reynolds, P.C., Two Militia Drive, Lexington, MA
02421 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- With international search report.
- Before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments.

(88) Date of publication of the international search report:
25 May 2001

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: **BDNF POLYMORPHISM AND ASSOCIATION WITH BIPOLAR DISORDER**

(57) Abstract: Methods for diagnosing and treating neuropsychiatric disorders, especially bipolar disorder, and to methods for identifying compounds for use in the diagnosis and treatment of neuropsychiatric disorders are disclosed. Also disclosed are novel compounds and pharmaceutical compositions for use in the diagnosis and treatment of neuropsychiatric disorders such as bipolar disorder.

WO 01/11085 A3

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/21859

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12Q1/68 A61K38/18 A61P25/18 A61K48/00 G01N33/53
G01N33/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12Q A61K A61P G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, CHEM ABS Data, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 450 386 A (SYNERGEN INC) 9 October 1991 (1991-10-09) page 22, line 25 - line 29 claims 2,5,8 figure 1	6,8,10, 12
A	KREBS, M. O. ET AL.: "Association Study of Brain-Derived Neurotrophic Factor (BDNF) Polymorphism in Schizophrenia" AM. J. MED. GENET., vol. 81, no. 6, 1998, page 520 XP000990211 the whole document	1-24

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

13 March 2001

Date of mailing of the international search report

26/03/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Mata Vicente, T.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

The search was done based on the assumption that the amino acid at position -63 mentioned in the claims is the one that occupies that position in Fig. 1A (hB) of the application and, therefore, that the nucleotide position 424 to which the claims refer is nucleotide position 404 of the said figure (i.e. nucleotide position 404 of SEQ ID NO:2 of the sequence listing).

The applicant's attention is drawn to the fact that the polypeptide having SEQ ID NO:7 of the sequence listing does not correspond to the human polypeptide disclosed in Fig. 1A (hB). The existence in the former of at least three insertions as compared to the latter (which is the sequence contained in the Databanks) has been observed and, therefore, it has not been regarded as the product subject of the present invention and has not been searched.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/21859

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0450386 A	09-10-1991	US 5235043 A	10-08-1993
		AT 183232 T	15-08-1999
		AU 651339 B	21-07-1994
		AU 7413091 A	14-11-1991
		CA 2038669 A	07-10-1991
		DE 69131514 D	16-09-1999
		DE 69131514 T	04-05-2000
		DK 450386 T	06-03-2000
		ES 2140379 T	01-03-2000
		FI 911643 A	07-10-1991
		GR 3031632 T	31-01-2000
		IE 910827 A	09-10-1991
		JP 2521851 B	07-08-1996
		JP 6319549 A	22-11-1994
		NO 911303 A	07-10-1991
		NZ 237544 A	27-07-1993
		US 5606031 A	25-02-1997
		US 5986070 A	16-11-1999
		ZA 9101834 A	26-02-1992